Biogen’s Leqembi to drive Alzheimer’s market to $14B in 2030

filadendron/E+ via Getty Images

Driven by new therapies from Biogen (Nasdaq: BIIB) / Esay (OTCPK: ESALF) and Eli Lilly (New York Stock Exchange: LLY), the Alzheimer’s disease market in eight major countries will reach $13.7 billion in 2030, data analytics firm GlobalData said last week.

This means compound annual growth

14BAlzheimersBiogensdriveLeqembimarket
Comments (0)
Add Comment